DENTSPLY SIRONA Inc. (XRAY) reported second-quarter 2026 adjusted earnings per share (EPS) of 52 cents, a 1.6% year-over-year decline, but exceeding the Zacks Consensus Estimate of 36 cents by 44.4%. Revenues fell 4.1% to $898 million, surpassing the consensus by 1.6%, amid weakness in three dental segments, partially offset by growth in Wellspect Healthcare.
Segment revenues included: Connected Technology Solutions at $239 million (down 1.5%), Essential Dental Solutions at $376 million (down 2.7%), and Orthodontic and Implant Solutions at $197 million (down 13.2%). Wellspect Healthcare increased revenues by 7.1% to $86 million. Geographically, the Americas saw a revenue decline of 10.7%, while EMEA reported a slight increase of 0.2% and APAC a drop of 1% in sales.
DENTSPLY SIRONA maintained its full-year 2026 guidance for net sales between $3.5 billion to $3.6 billion and adjusted EPS of $1.40-$1.50. The Zacks Consensus Estimate currently stands at $3.58 billion for sales and $1.42 for adjusted EPS.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
